ExpreS2ion Biotech Holding AB is planning an Initial Public Offering and listing on Nasdaq Stockholm First North
ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby announces on May 26th 2016 that the company is planning an Initial Public Offering during June 2016 with planned listing on Nasdaq Stockholm First North. Fully subscribed, this offering will provide revenues of 18 MSEK to ExpreS2ion.About ExpreS2ion ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through their wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of new vaccines and